Premium
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 ‐internal tandem duplication genotypes
Author(s) -
Boddu Prajwal C.,
Kadia Tapan M.,
GarciaManero Guillermo,
Cortes Jorge,
Alfayez Mansour,
Borthakur Gautam,
Konopleva Marina,
Jabbour Elias J.,
Daver Naval G.,
DiNardo Courtney D.,
Naqvi Kiran,
Yilmaz Musa,
Short Nicholas J.,
Pierce Sherry,
Kantarjian Hagop M.,
Ravandi Farhad
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31885
Subject(s) - medicine , npm1 , idarubicin , cytarabine , myeloid leukemia , oncology , cohort , retrospective cohort study , gastroenterology , biochemistry , chemistry , karyotype , chromosome , gene
Background The revised 2017 European LeukemiaNet (ELN) classification (ELN‐2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms‐like tyrosine kinase 3 ( FLT3 )–internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN‐2017 in comparison with ELN‐2010 in younger patients with AML has not been validated to date. Methods The authors performed a retrospective study on patients aged <60 years who received idarubicin plus cytarabine (IA)–based induction chemotherapy for newly diagnosed AML. Results According to ELN‐2017 criteria, the number of patients in the favorable (Fav), intermediate (Int), and adverse (Adv) risk categories was 192 patients (27%), 331 patients (46%), and 192 patients (27%), respectively. Overall survival probabilities at 5 years in the Fav, Int, and Adv groups were 57%, 37%, and 18%, respectively. In comparison, the 5‐year overall survival probabilities in the Fav (169 patients), intermediate (IR)‐1 (80 patients), IR‐2 (306 patients), and Adv (160 patients) ELN‐2010 categories were 59%, 32%, 40%, and 14%, respectively. Although ELN‐2010 historically distinguishes prognosis into IR‐1 and IR‐2 categories in younger patients, this difference was nullified in the current study cohort. When comparing patients with a low FLT3 ‐ITD AR with those with a high FLT3 ‐ITD AR, no significant differences in survival were noted among patients with nucleophosmin 1 ( NPM1 )‐mutated AML ( P = .28) or wild‐type NPM1 ( P = .35), and in those treated with IA alone ( P = .79) or those treated with IA and a FLT3 inhibitor ( P = .10). Conclusions The ELN‐2017 more accurately distinguishes prognosis in patients with newly diagnosed AML. The lack of prognostic significance for the FLT3 ‐ITD AR needs further evaluation in different treatment settings.